Iminosugars, which carry a basic nitrogen in the carbohydrate ring, have attracted increasing interest as new glycomimetics. Gem-diamine 1-N-iminosugars, a new class of iminosugars, have a nitrogen atom in place of the anomeric carbon. Various kinds of 1-N-iminosugars have been synthesized from glyconolactones as a chiral source in a totally stereospecific manner and/or by the convergent strategy from siastatin B, a secondary metabolite of Streptomyces. The protonated form of 1-N-iminosugar mimics the charge at the anomeric position in the transition state of enzymatic glycosidic hydrolysis, resulting in a strong and specific inhibition of glycosidases and glycosyltransferases. They have been recently recognized as a new source of therapeutic drug candidates in a wide range of diseases associated with the carbohydrate metabolism of glycoconjugates, such as tumor metastasis, influenza virus infection, lysosomal storage disorder and so forth.
INTRODUCTION
Iminosugars, which are carbohydrate analogs that most frequently carry the nitrogen atom at the position of the endocyclic oxygen, form the most attractive class of glycomimetics reported so far. 1 Several types of iminosugars have been discovered from natural sources 1,2 since nojirimycin 3 was first isolated as an antibiotic from Streptomyces culture in 1966. Many more have also been synthesized on the basis of enzymatic glycoside biosynthesis. 1, 4 Of late, they have gained remarkable importance not only as molecular tools to unravel the manner in which glycoconjugates regulate various biological functions, but also as new therapeutic agents in a wide range of diseases associated with the metabolism of carbohydrates.
In 1974, siastatin B (1), an unusual iminosugar, was isolated as an inhibitor against neuraminidases (NAs) from Streptomyces culture. 5 Siastatin B (1) also inhibits b-D-glucuronidase and N-acetylb-D-glucosaminidase. We recognized from biological activity that siastatin B (1) structurally resembles D-glucuronic acid (2) and N-acetyl-D-glucosamine (3), as well as N-acetylneuraminic acid (4) (Figure 1 ). It is distinct from the known glycosidase inhibitors, such as nojirimycin, that contain a nitrogen atom in place of the ring oxygen. In the course of our study on siastatin B (1), we proposed a new class of glycosidase inhibitors, gem-diamine 1-N-iminosugars [6] [7] [8] (gem-diamine 1-aza-carbasugar in IUPAC nomenclature, 9 cyclic methanediamine monosaccharide, 5) in which the anomeric carbon atom is replaced by nitrogen. We hypothesized that the protonated form of gem-diamine 1-N-iminosugar 6 may mimic the putative glycopyranosyl cation 7 that was formed during enzymatic glycosidic hydrolysis ( Figure 2 ). This turned out to be the case and led to new findings of highly potent and specific inhibitors of glycosidases and glycosyltransferases, as well as potential therapeutics for tumor metastasis and so forth. On the other hand, the synthetic isofagomine (8) , another type of 1-iminosugar, was developed by Bols and colleagues in 1994. 10 The isofagomine type 1 iminosugars showed a potent inhibition of their corresponding b-glycosidase. 11 These findings suggest that 1-iminosugars might provide another alternative to the development of therapeutic agents based on the inhibitors of metabolism of glycoconjugates different from the common iminosugars, such as Zavesca (N-n-butyl-1-deoxynojirimycin) 12 used for the treatment of Gaucher's disease.
This review describes our current progress in the chemistry, biochemistry and pharmacology of gem-diamine 1-N-iminosugars.
SYNTHESIS
Various types of iminosugar inhibitors, such as polyfunctional piperidines and pyrrolidines, have been designed on the basis of a flattened, half-chair oxocarbenium ion-like transition state in the reaction catalyzed by glycosidases. [13] [14] [15] They are all carbohydrate mimics in which the ring oxygen is replaced by nitrogen. On the other hand, 1-N-iminosugars have a unique structure with a nitrogen atom in place of the anomeric carbon atom. Gem-diamine 1-N-iminosugars have an especially unusual structure possessing the continuous -CH(OH)-CH(OH)-CH-(NHR)-NH-CH2-CH(CH2OH/COOH)-in a framework. Their multi-functionalized structures with many asymmetric centers in a small molecule and fascinating biological activities have attracted intensive synthetic interest. As the interest in this class of glycomimetics comprised analogs of both D-and L-sugars, we have developed flexible divergent strategies applicable to a wide range of gem-diamine 1-N-iminosugars using glyconolactones as chiral substrates. Efficient and convenient synthetic methodologies of gem-diamine 1-N-iminosugars were also developed from natural siastatin B. These convergent strategies using natural siastatin B could be useful and practical for drug development.
Total synthetic route to gem-diamine 1-N-iminosugars The chiron strategy using D-ribono-g-lactone (9) was first adapted for the total synthesis of siastatin B (1) and its enantiomer. 16 ,17 D-galacturonic acid-type 2-acetamido-1-N-iminosugar was synthesized in a totally stereospecific and enantiospecific manner as shown in Scheme 1. 18 The strategy involves the formation of the cyclic methanediamine using the Mitsunobu reaction 19 on an aminal (14) (15) and the stereospecific introduction of a carboxylic acid group into a ketone (16) (17) (18) (19) (20) (21) as the key steps. The synthesis of the key intermediate, lactam 11, commenced with L-ribose, which was transformed into azido-L-ribonolactone 10 by the protection of 2,3-diol, azide formation and oxidation. Hydrogenation of the azide group of 10 resulted in crystalline 11 with ring expansion. Stereospecific introduction of the hydroxyl group at the C-2 position was best achieved by hydride reduction of the protected lactam 12 followed by the Swern oxidation to yield aminal 14. One-step stereospecific transformation of 12 into 14 was also efficiently achieved by the reduction of L-selectride in tetrahydrofuran. The Mitsunobu reaction with phthalimide in dimethylformamide was proved to quantitatively yield the desired cyclic methanediamine 15. Replacement of the amino substituent, removal of the tert-butyldimethylsilyl (TBDMS) group and oxidation to 16 were carried out straightforwardly. Condensation of 16 with nitromethane was found to proceed smoothly to quantitatively yield 17 as a single stereoisomer. The endocyclic nitro olefin 18 was effectively derived from 17 by acetylation followed by basecatalyzed elimination of the acetoxy group. The crucial intermediate, carboxylate 20, was obtained through a,b-unsaturated aldehyde 19 generated by simply warming in pyridine. Transformation of 20 into siastatin B (1) was best achieved by the following three-step sequences: stereoselective reduction to the a,b-saturated hydroxymethyl compound 21, oxidation and removal of protecting groups. The antipode of 1 was also synthesized from D-ribono-1,4-lactam using the abovementioned method. Thus, the total synthesis also elucidated the absolute configuration of siastatin B (1) as the (3S,4S,5R,6R) isomer.
The strategy of total synthesis of siastatin B (1) is applicable to a wide range of D-galacturonic acid-type gem-diamine 1-N-iminosugars (Schemes 2 and 3). 20, 21 Syntheses of D-galacturonic acid-type 2-acetamido-and trifluoroacetamido-1-N-iminosugars (27a and 27b) having a hydroxyl group at the C-5 position and their antipodes 27c and 27d are achieved in a straightforward manner. The nitromethane condensation of the ketones 23a and 23b stereospecifically proceeded to afford adducts 24a and 24b. The S-configuration at position C-5 was clarified by an X-ray crystallographic analysis of the antipode of 23a. Successive sequences of catalytic reduction, ninhydrin oxidation of the resultant aminomethyl group, oxidation of the resultant aldehyde with sodium chlorite and removal of the protecting groups afforded the final products. The antipodes 27c and 27d were also synthesized starting from D-ribono-1,4-lactone using similar methods that are mentioned above.
An alternative route from the ketone 23b to D-galacturonic acidtype 2-trifluoroactamido-1-N-iminosugar 32 was also developed Figure 2 General structures of gem-diamine 1-N-iminosugars (5), its protonated form (6), glycopyranosyl cation (7), the putative intermediate of enzymatic glycosidic hydrolysis and isofagomine (8) , another type of 1-iminosugar.
using the Wacker process oxidation of the enol ethers 28 and 29 as a key step. The Wacker process oxidation stereospecifically proceeded to yield carboxylate 30 as a sole product. The transformation of 30 into 32 was unexceptional.
A flexible synthetic route to four gem-diamine 1-N-iminosugars of D-and L-uronic acid type (D-glucuronic, D-mannuronic, L-iduronic and L-guluronic acid) from L-galactono-1,4-lactone was also developed in an enantiodivergent manner through a sequence involving as the key steps (1) the formation of gem-diamine 1-N-iminopyranose ring by the Mitsunobu reaction of an aminal (44) (45) 46) and (2) the flexible introduction of a carboxylic acid group by the Wittig reaction on a ketone, followed by hydroboration and oxidation, as well as the Sharpless oxidation (45 and 46-47, 48 and 55, 56) (Schemes 4 and 5). 22, 23 The diastereoselective construction of amino and carboxylic acid substituents at positions C-2 and C-5, respectively, on the versatile aminal 44 led to the formation of four enantiomerically pure stereoisomers (51, 54, 61 and 66) . The Wittig reaction on the ketone 37 derived from L-galactono-1,4-lactone resulted in the methylene derivative 38, which was converted into the diol 39. The monoalcohol 40 was successfully obtained by the Luche reduction of the labile aldehyde generated by the periodate oxidation of 39. Conversion of the hydroxyl group of 40 to the azide group was best achieved from the corresponding sulfonate by one-pot reaction in situ. Hydrogenation of the azide group of 41 with sodium hydrogentelluride (NaTeH) was found to proceed preferentially without any effect on the reduction of the methylene group. The pivotal intermediate, aminal 44 was obtained as an epimeric mixture by the removal of a TBDMS group and the Swern oxidation. The Mitsunobu reaction with phthalimide afforded both desired epimers of iminophthalimides 45 and 46 in a 3:1 ratio. The absolute stereochemistry and a boat conformer of 45 were clarified by an X-ray crystallographic analysis. Another epimer 46 was assigned its stereochemistry and boat conformation by the hydrogen-1 nuclear magnetic resonance ( 1 H-NMR) spectrum. Hydroboration of 45 followed by oxidation efficiently yielded the D-gluco isomer 47 and the L-idulo isomer 48 in a 2:9 ratio. Hydrazinolysis of 47 and conventional trifluoroacetylation furnished the trifluoroacetamide 49. The ruthenium tetraoxide-catalyzed Sharpless oxidation effectively yielded the carboxylic acid 50. 
acid-type and L-guluronic acid-type 1-N-iminosugars 61 and 66 were prepared in a straightforward manner by a similar sequence of structure transformation, except for the protection of the hydroxyl groups of 55 and 56 before hydrazinolysis of the phthalimide group for improvement in yield. The 1 H-NMR spectra of 61 and 66 showed the boat and 1 C 4 -conformations, respectively.
An enantioselective synthesis of L-fucose-type gem-diamine 1-Niminosugars from D-ribono-g-lactone was developed that used the Mitsunobu reaction on an aminal in the gem-diamine 1-N-iminopyranose ring formation (74) (75) and a stereospecific reduction of an exo-methylene group to form the correct configuration of L-fucose (75-76) (Scheme 6). 24, 25 The synthesis of the pivotal intermediate, Intermediates prepared during the total synthetic route to uronic acid-type gem-diamine 1-N-iminosugars are also available for the synthesis of various kinds of glycose and glycosamine-type gem-diamine 1-N-iminoisugars (Scheme 7). 22 Semi-synthetic route to gem-diamine 1-N-iminosugars Natural siastatin B (1) can also serve as a starting material in a simple and easy route to D-galacturonic acid-type gem-diamine 1-N-iminosugars (Scheme 8). 26, 27 Transketalization using chlorotrimethylsilane successfully proceeded to yield the ketal 94. A sequence of esterification, hydride reduction and hydrazinolysis efficiently afforded the amino alcohol 97, which was converted into the trifluoroacetamide 98. The ruthenium-catalyzed Sharpless oxidation followed by the removal of the protecting group resulted in the desired product 32. 2-Trichloroacetamido, guanidino and phthaloyl analogs 106, 107 and 108 were also prepared using similar methods.
Configurational inversion of the carboxyl group of siastatin B (1) leads to gem-diamine 1-N-iminosugars corresponding to L-sugars. 28, 29 The intramolecular Michael addition of O-imidate to the a,b-unsaturated ester through cis oxiamination 30 (Overman rearrangement, 110-111) as a key step effectively yielded L-uronic acid-type gem-diamine 1-N-iminosugars (Schemes 9 and 10). The a,b-unsaturated ester 110 readily available from siastatin B (1) smoothly underwent cis oxiamination through the conjugate addition of the intermediate imidate anion to result in the desired oxazoline 111 in a good yield and a trace amount of its epimer. Hydrolysis of 111 afforded the trichloroacetamides 112 and 113, which were converted into the amines 114 and 115, respectively, on reductive cleavage of the trichloroacetamide group. Removal of the protecting groups of 114 and 115 resulted in L-alturonic acid-type and L-mannuronic acid-type 2-acetamido-1-N-iminosugars 116 and 117, respectively. Another type of L-alturonic acid-type 2-acetamido-1-N-iminosugar 119 with a guanidine group was also obtained by the conventional method. The 1 H-NMR spectra of 116, 117 and 119 showed 1 C 4 -conformations. 2-Trifluoroactamide analogs 130 and 133 were also prepared by a similar sequence of reactions using the a,b-unsaturated ester 123 readily available from 97.
Siastatin B (1) has the correct configuration corresponding to D-galactose-and D-galactosamine-type gem-diamine 1-N-iminosugars. Therefore, the various kinds of D-glycose and D-glycosaminetype gem-diamine 1-N-iminosugars could be obtainable by a semi-synthetic method starting from 1 (Schemes 11 and 12) 30 
Configurational inversions at the C-4 position of 144 and 145 by two-step reactions led to the facile synthesis of D-glucosamine and glucose-type gem-diamine 1-N-iminosugars 150 and 151, respectively (Scheme 13). 32 BIOLOGICAL ACTIVITY Glycoconjugates such as glycoprotein, glycolipid and proteoglycan are ubiquitous in nearly all forms of life and are involved in cell-to-cell communication, cell-to-cell recognition, cell adhesion, cell growth regulation, differentiation and transport. Specific inhibitors of glycosidase and glycosyltransferases are useful for unraveling the manner in which glycoconjugates regulate biological function, and also for developing new drugs for a wide range of diseases associated with both the biosynthesis and degradation of glycoconjugates, namely cancer, tumor metastasis, diabetes, lysosomal storage disorders, viral and bacterial infections and so forth. Iminosugars generally show potent and specific inhibition against glycosidases and glycosyltransferases from various organisms. 1, [33] [34] [35] Of these, gem-diamine 1-N-iminosugars have been proven to be highly potent and specific inhibitors of glycosidases, glycosyltransferases and sulfotransferases, and also potential therapeutics for tumor metastasis, lysosomal storage disorders and other diseases. 1, 6, [36] [37] [38] Glycosidase, glycosyltransferase and sulfotransferase inhibitory activity The inhibitory activities of L-fucose-type gem-diamine 1-N-iminosugars against glycosidases are summarized in Table 1 . 24, 25 The L-fucose-type 2-trifluoroacetamide 84 showed a very strong and specific inhibition against a-L-fucosidase from bovine kidney. Compound 84 was proved to be a competitive inhibitor by the Lineweaver-Burk plot, and the Ki value of 84 was determined as 5Â10 À9 M by the Dixon plot. 25 The 2-trichloroacetamide 85 and 2-phthalimide 86 also strongly affected a-L-fucosidase equivalent to the trifluoroacetamide 84. Compounds 84, 85 and 86 have been proven to smoothly undergo the Amadori rearrangement to yield the common intermediates, the hemiaminal 152 and the hydrated ketone 153 at pH 6.3 ( Figure 3 ). 39 The time-course evaluation of inhibitory activities of 84, 85 and 86 in the medium indicates that the hemiaminal and the hydrated ketone generated in the medium strongly inhibit a-L-fucosidase as the real active form. The 1 H-NMR spectra of the hemiaminal 152 and the hydrated ketone 153 also clearly show their 1 C 4 -conformation. Interestingly, the hemiaminal 152 has the same structure as that of synthetic L-fuconoeuromycin. 11,40 L-fuco-noeuromycin shows a potent inhibition against a-L-fucosidase equivalent to compounds 84, 85 and 86. On the other hand, the stable acetamide 83 in the medium shows a moderate inhibition against a-L-fucosidase. These results support the hypothesis that the protonated gem-diamine 1-N-iminosugars may mimic the presumed glycosyl cation 7 in the transition state of the enzymatic reaction as shown in Figure 2 . Compounds 87 and 88 show a weak inhibition against a-L-fucosidase. These results also indicate that the 5-methyl group, its stereochemistry and the 1 C 4 -conformation have important roles as major factors for potency and specificity. 
The inhibitory activities of uronic acid-type gem-diamine 1-Niminosugars against glycosidases are summarized in Table 2 . 7, [20] [21] [22] 26, 27 D-glucuronic acid-type 2-trifluoroacetamido-1-N-iminosugar 51 shows a very strong inhibition against b-glucuronidase. D-uronic acid-type gem-diamine 1-N-iminosugars, similar to the L-fucosetype gem-diamine mentioned above, have been proven to smoothly undergo the Amadori rearrangement to yield the hydrated ketone 155 or its derivative 156 through a hemiaminal 154 at pH45.0 (Figure 4) . 39 The time-course evaluation of the inhibitory activity in the medium also indicates that the hemiaminal and hydrated ketone generated in the medium strongly inhibits glycuronidases. It is reasonable to expect that the hemiaminal and hydrated ketone and Role of gem-diamine 1-N-iminosugars Y Nishimura its equivalent generated from 51 in the medium should closely mimic a glycopyranosyl cation that could adapt either a chair-like or a flattened conformational 157 and 158, respectively, in the putative transition state of b-glucuronidase hydrolysis ( Figure 5 ). D-galacturonic acid-type 2-trifluoroacetamido-, 2-trichloroacetamido-, 2-guanidino-and 2-phthalimido-1-N-iminosugars 27b, 32, 106, 107 and 108 also strongly inhibit glucuronidase. These results indicate that b-glucuronidase roughly recognizes the configuration of the 4-OH group of glycopyranose and/or that the binding group of b-glucoronidase to the 4-OH has no important role in the specificity. Interestingly, D-mannuronic acid-type 2-trifluoroacetamido-1-Niminosugar 61 also shows a strong inhibition equivalent to those of Role of gem-diamine 1-N-iminosugars Y Nishimura ( Figure 5 ). On the other hand, the stable analogs 1 and 27a in the media expectedly show only a weak inhibitory activity against b-glucuronidase. Role of gem-diamine 1-N-iminosugars Y Nishimura pBK-CMV expression vectors containing the heparanase cDNA (Table 3) . 22, 41 Heparanase is an endo-b-glucuronidase that specifically cleaves the b-1,4 linkage between D-glucuronic acid and N-acetyl-D-glucosamine of heparan sulfate (HS) side chains of HS proteoglycans (HSPGs). The relationships between activity against heparanase and the inhibitor structures are also similar to those discussed regarding the inhibition against exo-b-glucuronidase from bovine liver. The weaker activity against heparanase than that against exo-b-glucuronidase suggests that heparanase should simultaneously recognize D-glucuronic acid and the adjacent glycoses on both sides of D-glucuronic acid. As expected, all of the L-uronic acid-type gem-diamine 1-N-iminosugars (54, 66, 116, 117, 119, 130 and 133) show no remarkable inhibition against these D-sugar hydrolases. These results indicate that glycohydrolases recognize precisely the absolute configurations of gem-diamine 1-Niminosugars corresponding to the D-and L-sugars for specificity and potency. Figure 4 Structural changes of D-galacturonic acid-type gem-diamine 1-N-iminosugars in medium at pH 5.0.
Role of gem-diamine 1-N-iminosugars Y Nishimura
The inhibitory activities of D-glycose-and D-glycosamine-type gemdiamine 1-N-iminosugars against glycosidases are summarized in Table 4 . [30] [31] [32] As expected, D-glucose-type 2-trifluoroacetamide 151 inhibits a-and b-D-glucosidases very strongly and specifically, and D-glucosamine-type 2-acetamide 150 shows a strong and specific inhibition against b-D-N-acetylglucosaminidase. On the other hand, D-galactosetype 2-trifluroacetamide 142 strongly inhibits not only a-and b-D-galactosidases but also b-D-glucosidase. D-galactosamine-type 2-acetamide 135 also strongly inhibits both a-D-N-acetylgalactosaminidase and b-D-N-acetylglucosaminidase. These results seem to indicate that the hemiaminals of the glycose-type inhibitors generated in the media mimic a transient intermediate 7 (Figure 2 ) in the hydrolysis of glycosidases, and that the glycosamine-type inhibitors themselves mimic a glycopyranoside in its grand state during the hydrolysis of glycosaminidases. These results also suggest that the axial 4-OH group is the main determinant for specificity and potency of the inhibitors against D-galacto-type hydrolases. However, D-gluco-type hydrolases may roughly recognize the stereochemistry of the 4-OH group and accept both axial and equatorial configurations. N-acetylglycosaminidases also recognize the 2-N-acetyl group precisely.
D-galacturonic acid-type 2-trifluoroacetamido-1-N-iminosugar having a hydroxyl group at the C-5 position 27b inhibits sialyltransferase nearly as well as cytidine 5¢-diphosphate, a standard inhibitor, in the mouse mammary carcinoma mutant cell line (FUA169), 42 which has a high transfer activity of sialic acid to lactosylceramide [Galb1-4Glcb1-1Cer] to form ganglioside GM3 [NeuAca2-3Galb1-4Glcb1-1Cer] (Table 5 ). This result suggests that 27b may resemble a gem-diamine 5-N-iminosugar and mimic sialic acid (4) in the sialyltransferase reaction ( Figure 6 ). This is similar to the method in which siastatin B (1) mimics 4 in NA (N-acetylsialidase) hydrolysis (Figure 1) .
L-altruronic acid-type 2-acetamido-1-N-iminosugar 119 and its 1-N-2-ethlybutyrylamide (159) also inhibit HS 2-O-sulfotransferase (HS 2-O-ST) over 80% at 25 mM. 43 HS 2-O-ST transfers the sulfate group from the sulfate donor, adenosine 3¢-phosphate-5¢-phosphosulfate, to the 2-OH group of L-iduronic acid of HS, which is composed of a repeating disaccharide unit comprising glucosamine (GlcN) and hexuronic acid (D-glucuronic acid or its C-5 epimer, L-iduronic acid). 44 This result indicates that HS 2-O-ST recognizes 119 and 159 as L-iduronic acid. Molecular modeling using PM3 in MOPAC shows the structural similarity between a-L-iduronic acid and 119 (Figure 7) . 29 As shown in Figure 7 , 119 superimposes well on a-L-iduronic acid and the acetamido and guanidino moieties of 119 are also topographically equivalent to the hydroxyl moieties of a-L-iduronic acid.
Inhibition of esophageal keratinocyte differentiation
Recently, it has been clarified that heparanase is localized in the cell nucleus of the normal esophageal epithelium and esophageal cancer, 45 and that its expression is correlated with cell differentiation. 46 On esophageal cell differentiation, heparanase is translocated from the cytoplasm to the nucleus. On such translocation, heparanase degrades the glycan chain of HS in the nucleus, and changes in the expression of keratinocyte differentiation markers such as p27 and involucrin are observed. D-galacturonic acid-type gem-diamine 1-Niminosugar 32 inhibits efficiently this degradation and induction in the nucleus. 47 It has been shown that heparanase regulates the Abbreviations: CDP, cytidine 5¢-diphosphate. The sialyltransferase activity was determined according to the method of Hakomori et al. 34 using mouse mammary carcinoma mutant cell line (FUA 169), which shows high activity of CMP-sialic acid:LacCer 2,3-sialosyltransferase.
Role of gem-diamine 1-N-iminosugars Y Nishimura differentiation of normal esophageal epithelium through nuclear translocation and nuclear HS cleavage and has an important role in the development of normal esophageal epithelium.
Inhibition of microglial cell migration
Very recently, microglia, the resident macrophages in the brain, have been found to express heparanase mRNA and protein, which can degrade the glycan chain of HSPGs. 48 Heparanase activity is correlated with the in vitro transmigration ability of microglia through an artificial basement membrane (BM)/extracellular matrix (ECM) containing HSPGs. D-galacturonic acid-type gem-diamine 1-N-iminosugar 32 inhibits this process in a dose-dependent manner. 48 The transmigration of microglia through BM/ECM appears to be associated with the degradation of HSPG, and this is also inhibited dose dependently by 32. The results suggest the involvement of heparanase in the migration or invasion of microglia or brain macrophages across the BM around the brain vasculature. 6 ) by intra-footpad injection were administered intravenously (i.v.) with 32 for 5 days starting on the day of the surgical excision of primary tumors on day 9. Mice were killed 10 days after tumor excision. *Po0.01.
THERAPEUTIC POTENTIALS Tumor metastasis
Recent biochemical studies have shown that cellular function and phenotype are highly influenced by HSPGs of ECM, and that the enzymatic degradation of ECM is involved in fundamental biological phenomena, including angiogenesis and cancer metastasis. [49] [50] [51] [52] [53] Proteolytic enzymes (heparanase and matrix metalloproteinases) secreted by tumor cells are capable of degrading ECM and BM components, and their activities are closely related to the metastasis potential of malignant cells. [54] [55] [56] [57] [58] [59] [60] The inhibitory effects of uronic acid-type gem-diamine 1-N-iminosugars that have inhibitory activities against exo-uronidase, heparanase, sulfotransferase and sialyltransferase were also evaluated on tumor metastasis using the experimental and spontaneous pulmonary metastasis in mice.
D-galacturonic acid-type gem-diamine 1-N-iminosugars 27b, 32, 106 and 107 that have inhibitory activities against exo-uronidase and heparanase significantly suppress in a dose-dependent manner the number of colonies of pulmonary metastasis of B16BL6 cells in the experimental metastasis (Table 6) . 6, 7, 26, 27 Of these, 2-trifluoroacetamide 32 inhibits pulmonary metastasis most potently.
L-altruronic acid-type gem-diamine 1-N-iminosugars 116, 119, 130 and 133 that have inhibitory activity against HS 2-O-ST also reduce remarkably in a dose-dependent manner the pulmonary colonization of B16BL6 cells in the experimental metastasis (Table 7) . 28 Of these, 2-acetamido-4-guanidino-1-N-iminosugar 119 inhibits the experimental metastasis very strongly.
As shown in Table 8 , the inhibition of spontaneous lung metastasis in mice by the intravenous (i.v.) injection of 32 is more noticeable. 6, 61 Compound 32 shows 57% inhibition of metastasis by the administration of 100 mg kg À1 per day for 5 days.
On the other hand, D-galacturonic acid-type 32 and L-altruronic acid-types 119 and 133 inhibit in a dose-dependent manner the transmigration of B16BL6 and 3LL cells through the reconstituted BM (Matrigel) by in vitro treatment (Tables 9 and 10 ). 8, 61 Gem-diamine 1-N-iminosugars related to D-glucuronic and L-iduronic acids markedly inhibit the experimentally induced lung metastasis of B16BL6 and/or 3LL cells, and also the spontaneous lung metastasis of 3LL cells after i.v. administration. D-uronic acid-type iminosugars inhibit tumor heparanase activity, an effect that probably results from their resemblance to D-glucuronic acid as a substrate for tumor heparanase. L-uronic acid-type iminosugars inhibit HS 2-O-ST activity, an effect that probably results from their resemblance to L-iduronic acid as a substrate for HS 2-O-ST. Furthermore, gem-diamine 1-N-iminosugars prevent the transmigration of B16BL6 and/or 3LL cells through the reconstituted BM with no cytotoxicity. These results suggest that the anti-metastatic effect of the iminosugars may be due to their anti-invasive rather than their Role of gem-diamine 1-N-iminosugars Y Nishimura anti-proliferative activities. It is likely that gem-diamine 1-N-iminosugars related to D-glucuronic and L-iduronic acids act as the mimic of respective uronic acids in the metabolism of ECM and/or BM involved in tumor metastasis. These iminosugars seem to modify the cell surface glycoconjugates of tumor cells simultaneously, thereby altering the cell properties involved in cellular recognition and adhesion.
Influenza virus infection
Some of the uronic acid-type gem-diamine 1-N-iminosugars could also mimic sialic acid (4) in the sialidase (N-acetyneuraminidase) reaction as an alternative type of gem-diamine 5-N-iminosugar such as siastatin B (1) (Figure 1) . Two integral membrane glycoproteins, hemagglutinin (HA) and NA, of the influenza virus were proved to have important roles at the beginning of infection and during the spread of the infection, [61] [62] [63] [64] [65] [66] respectively, and it has been postulated that the inhibitors of HA and NA should have antiviral properties. NA is a glycosidase that cleaves the a-ketosidic bond linking the terminal sialic acid to the adjacent oligosaccharide residues of glycoproteins and glycolipids. 67, 68 In 1992, the binding modes of sialic acid to NAs of the influenza virus B/Beijin/ 1/87 and A/Tokyo/3/67 were clarified to involve the characteristic a-boat conformation. 69, 70 3-Episiastatin B (160) shows specific potent inhibitory activities against influenza virus NAs and the influenza virus infection in the MDK cell in vitro (Tables 11 and 12 ). 71 Its activity is almost comparable with that of DDNA 161, a standard inhibitor. The lowest energy boat conformer of 160 obtained by molecular modeling using PM3/ MOPAC is superimposed onto the a-boat conformer of 4 in a pocket of the active site residue of the crystal structure of influenza virus B/Beijin/1/87 NA complex with 4 by a docking experiment using BIOCES/AMBER 6 ( Figure 8) . Compound 160 was shown to be a possible lead compound for anti-influenza virus agents.
Lysosomal storage disease Lysosomal storage disease, in which specific enzymes of glycoconjugate degradation are deficient, is an inherited storage disorder characterized by the accumulation of partially degraded molecules in lysosomes, eventually resulting in cell, tissue and organ dysfunctions. 74 The strategies for overcoming the deficit in enzyme capacity is to provide an endogenous supply of completely functional enzymes by direct infusion or by cellular replacement with cells capable of secreting enzymes (bone marrow replacement) or by gene delivery. [75] [76] [77] An alternative to enzyme replacement is to reduce substrate influx to the lysosome by inhibiting the synthesis of glycoconjugates. This strategy has been called substrate reduction therapy. [78] [79] [80] By balancing the rate of glycoconjugate synthesis with the impaired rate of glycoconjugate breakdown, the substrate influxefflux should be regulated to rates that do not lead to storage.
The enzyme deficient in Hunter's syndrome (MPS II) is iduronate 2-O-sulfatase, which functions by removing a 2-O-sulfate group from the iduronic acid unit of HS. [81] [82] [83] As mentioned above in the section 'Total synthetic route to gem-diamine 1-N-iminosugars,' compounds 119 and 159 inhibit strongly recombinant iduronate 2-O-ST over 80% at 25 mM. 43 Therefore, a partial inhibition of iduronate 2-O-ST by these iminosugars would reduce the build-up of the sulfated iduronic acid of HS in cells.
On the other hand, an alternative strategy, chemical chaperon therapy has been proposed for lysosomal storage disease, on the basis of a paradoxical phenomenon that states that an exogenous competitive inhibitor of low molecular weight stabilizes the target mutant protein and restores its catalytic activity as a molecular chaperon. [84] [85] [86] [87] A competitive inhibitor binds to a misfolded mutant protein as a molecular chaperon in the endoplasmic reticulum/Golgi apparatus of the cell, resulting in the formation of a stable complex at neutral pH and transport of the catalytically active enzyme to lysosomes, in which the complex dissociates under acidic conditions and the mutant enzyme remains stabilized and functional. Some iminosugars have shown remarkable efficacy for chemical chaperon therapy of Fabry and Gaucher's disease in clinical trials. 88 Gem-diamine 1-N-iminosugars have proven to be highly potent and specific competitive inhibitors against glycosidases, glycosyltransferases and sulfotransferases. These facts suggest that gem-diamine 1-N-iminosugars would be reasonable candidates for chemical chaperon therapy in lysosomal storage diseases, and that they are in principle applicable to all types of lysosomal storage diseases.
The main advantage of these therapies is the potential ability of the inhibitors as small molecules to cross the blood-brain barrier (BBB) and elicit a favorable response in the central nervous system (CNS). The difficulties in delivering proteins (enzymes) or genes to the CNS are not apparent using a small molecule that can cross the BBB easily. The therapy using iminosugars has the potential to prevent and/or reverse the effects of lysosomal storage disease both in the body and in the brain.
CLOSING REMARKS
This article describes our current progress in the chemical, biochemical and therapeutic potential of gem-diamine 1-N-iminosugars, a new family of glycomimetics, with a nitrogen atom in place of the anomeric carbon. Mechanistically, the protonated form of new glycomimetics may act as a mimic of a glycopyranosy cation and/or the transition state formed during enzymatic glycosidic hydrolysis. New inhibitors that mimic the charge at the anomeric position of the transition state have proven to be potent and specific inhibitors of various kinds of glycosidases.
New inhibitors that affect some metabolic enzymes of glycoconjugates have been found to participate in tumor metastasis. Uronic acidtype gem-diamine 1-N-iminosugars certainly contribute to the study regarding the involvement of carbohydrates in malignant cell movement and seem to be a promising new drug candidate for cancer chemotherapy. The N-acetylneuraminic acid-type iminosugar has shown potency against influenza virus infection, indicating a possible drug candidate that inhibits NA. It is also likely that gem-diamine 1-N-iminosugar, a new family of glycomimetics, is a reasonable drug candidate for chemical chaperon therapy and/or substrate reduction therapy in lysosomal storage disorder.
Iminosugars have proven to be a rich source of therapeutic drug candidates in the past several years and have thus become the special focus of research attention. Of these, gem-diamine 1-N-iminosugars have been recently recognized as a new source of therapeutic drug candidates in a wide range of diseases associated with the carbohydrate metabolism of glycoconjugates.
